This Article Full Text Full Text (PDF) All Versions of this Article: 200502-235PPv1 173/1/16    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, A. G. Articles by Ruckdeschel, J. C. Search for Related Content PubMed PubMed Citation Articles by Schwartz, A. G. Articles by Ruckdeschel, J. C.

Familial Lung Cancer

Genetic Susceptibility and Relationship to Chronic Obstructive Pulmonary Disease

Population Studies and Prevention Program, Karmanos Cancer Institute; and Department of Internal Medicine, Wayne State University, Detroit, Michigan

Correspondence and requests for reprints should be addressed to Ann G. Schwartz, Ph.D., Karmanos Cancer Institute, 110 East Warren Avenue, Detroit, MI 48201. E-mail: schwarta{at}med.wayne.edu

ABSTRACT

Lung cancer continues to be the leading cause of cancer death, and although most lung cancer is attributable to cigarette smoking, underlying genetic susceptibility is suggested by studies demonstrating familial aggregation. The first family linkage study of lung cancer has identified linkage of lung, laryngeal, and pharyngeal cancer in families to a region on chromosome 6q23–25. Because lung cancer and chronic obstructive pulmonary disease (COPD) are known to aggregate in families beyond shared risk associated with smoking, the linkage results are compared and contrasted with results from genomewide linkage and association studies and candidate gene studies searching for genes for lung cancer, lung function, and COPD. Linkage on chromosome 6q to both lung cancer and lung function, and on 12 to lung cancer, COPD, and lung function, together with overlap in candidate genes for these outcomes, suggests that future research into underlying genetic mechanisms of lung disease would benefit from broadening the collection of family history data and better defining the "high risk" population. As familial risk of lung disease is better defined, referral into screening programs and prevention trials can be better targeted to reach families with both a history of lung cancer and COPD.

Key Words: chronic obstructive pulmonary disease • genetics • linkage • lung cancer

This article has been cited by other articles:

				L. Marek, K. E. Ware, A. Fritzsche, P. Hercule, W. R. Helton, J. E. Smith, L. A. McDermott, C. D. Coldren, R. A. Nemenoff, D. T. Merrick, et al. Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells Mol. Pharmacol., January 1, 2009; 75(1): 196 - 207. [Abstract] [Full Text] [PDF]

				K Hemminki, X Li, K Sundquist, and J Sundquist Familial risks for chronic obstructive pulmonary disease among siblings based on hospitalisations in Sweden J Epidemiol Community Health, May 1, 2008; 62(5): 398 - 401. [Abstract] [Full Text] [PDF]

				E.L. Crawford, T. Blomquist, D.N. Mullins, Y. Yoon, D.R. Hernandez, M. Al-Bagdhadi, J. Ruiz, J. Hammersley, and J.C. Willey CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions Carcinogenesis, December 1, 2007; 28(12): 2552 - 2559. [Abstract] [Full Text] [PDF]

				D. H. Au, J. W. Chien, and C. L. Bryson A Major Cause of Death in COPD and Risk Factors for Lung Cancer a Dilemma or a Mistake? Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 625 - 625. [Full Text] [PDF]

				Y. Sekine, Y. Yamada, M. Chiyo, T. Iwata, T. Nakajima, K. Yasufuku, M. Suzuki, and T. Fujisawa Association of Chronic Obstructive Pulmonary Disease and Tumor Recurrence in Patients With Stage IA Lung Cancer After Complete Resection Ann. Thorac. Surg., September 1, 2007; 84(3): 946 - 950. [Abstract] [Full Text] [PDF]

				S. Dubey and C. A. Powell Update in Lung Cancer 2006 Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 868 - 874. [Full Text] [PDF]

				C. A. Granville, N. Warfel, J. Tsurutani, M. C. Hollander, M. Robertson, S. D. Fox, T. D. Veenstra, H. J. Issaq, R. I. Linnoila, and P. A. Dennis Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen-Induced Murine Lung Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2281 - 2289. [Abstract] [Full Text] [PDF]

				L. E. Mechanic, E. D. Bowman, J. A. Welsh, M. A. Khan, N. Hagiwara, L. Enewold, P. G. Shields, L. Burdette, S. Chanock, and C. C. Harris Common Genetic Variation in TP53 Is Associated with Lung Cancer Risk and Prognosis in African Americans and Somatic Mutations in Lung Tumors Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 214 - 222. [Abstract] [Full Text] [PDF]

				A. M. Knaapen, N. Gungor, R. P. F. Schins, P. J. A. Borm, and F. J. Van Schooten Neutrophils and respiratory tract DNA damage and mutagenesis: a review Mutagenesis, July 1, 2006; 21(4): 225 - 236. [Abstract] [Full Text] [PDF]

				J. R. Jett and Y. E. Miller Update in lung cancer 2005. Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 695 - 697. [Full Text] [PDF]